{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-24-000242","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.795322+00:00","generated_at":"2026-05-30T08:40:42.906347+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B","bullets":["Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.","Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.","Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.","FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.","Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E)."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-24-000242","json":"https://secwatch.observer/filing/0000059478-24-000242.json","markdown":"https://secwatch.observer/filing/0000059478-24-000242.md","text":"https://secwatch.observer/filing/0000059478-24-000242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/0000059478-24-000242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000242/lly-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:40:42.906347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}